A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Acesso expandido
Acesso expandido
Disponível
- Disponível: o acesso expandido está atualmente disponível para este tratamento experimental, e os pacientes que não são participantes do estudo clínico podem obter acesso ao medicamento, biológico ou dispositivo médico sendo estudado.
- Não está mais disponível: o acesso expandido estava disponível para esta intervenção anteriormente, mas não está disponível atualmente e não estará disponível no futuro.
- Temporariamente indisponível: o acesso expandido não está disponível atualmente para esta intervenção, mas espera-se que esteja disponível no futuro.
- Aprovado para marketing: A intervenção foi aprovado pela Food and Drug Administration dos EUA para uso público.
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Estude backup de contato
- Nome: EU GSK Clinical Trials Call Center
- Número de telefone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Locais de estudo
-
-
-
Buenos Aires, Argentina, 1425
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Mariano Dioca
-
Capital Federal, Argentina, C1426ANZ
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Yanina Pfluger
-
Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Guillermo Mendez
-
Ciudad Autonoma de Buenos Aire, Argentina, C1431FWO
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Julieta Grasselli
-
Ciudad autOnoma de Bueno, Argentina, C1419AHN
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Samanta Straminsky
-
San Miguel de Tucumán, Argentina, T4000IHE
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ruben Segovia
-
-
-
-
Victoria
-
Melbourne, Victoria, Austrália, 3004
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- John Zalcberg
-
-
-
-
-
Barretos, Brasil, 14784-400
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Arinilda Bragagnoli
-
Florianópolis, Brasil, 88034-000
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ana Paula Stramosk
-
Natal, Brasil, 59075-740
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Sulene Oliveira
-
Porto Alegre, Brasil, 90020-090
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Andreas Lutz
-
Vitória, Brasil, 29043-260
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- GLAUCIO BERTOLLO
-
-
Piauí
-
Teresina, Piauí, Brasil, 64002-530
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Welligton Figueiredo
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Albiruni Abdul Razak
-
-
Quebec
-
Montreal, Quebec, Canadá, H3A 1A1
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Jonathan Noujaim
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Beijing, China, 100141
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Jian Li
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Chengdu, China, 610041
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Bo Zhang
-
Guangzhou, China, 510060
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Haibo Qiu
-
Guangzhou, China, 510655
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Yanhong Deng
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Guangzhou, China, 510080
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Xinhua Zhang
-
Hangzhou, China, 310016
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Yu Zheng
-
Jinan, China, 250021
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Lei Cong
-
Nanjing, China
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Hao Xu
-
Shanghai, China, 200000
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ye Zhou
-
Shanghai, China, 20001
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Ming Wang
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Wuhan, China, 430022
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Kai-Xiong Tao
-
Zhengzhou, China, 450052
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Yang Fu
-
-
-
-
-
Seongnam-si Gyeonggi-do, Coréia do Sul, 13620
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ji-Won Kim
-
Seoul, Coréia do Sul, 03080
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Do-youn Oh
-
Seoul, Coréia do Sul, 03722
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Minkyu Jung
-
Seoul, Coréia do Sul, 138-736
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Min-Hee Ryu
-
Seoul, Coréia do Sul, 03181
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Dong-Hoe Koo
-
Suwon Kyunggi-do, Coréia do Sul, 16499
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Tae Hwan Kim
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Coréia do Sul, 06351
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Jungyong Hong
-
-
-
-
-
BaracaldoVizcaya, Espanha, 48903
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Alberto Muñoz Llarena
-
Barcelona, Espanha, 8025
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Raul Teres Lleida
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Madrid, Espanha, 28046
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Virginia Martinez Marin
-
Madrid, Espanha, 28034
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- María Ángeles Vaz Salgado
-
Madrid, Espanha, 28040
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Nadia Hindi Muñiz
-
Madrid, Espanha, 28041
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Aránzazu Manzano Fernández
-
Oviedo, Espanha, 33011
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Maria del Pilar Solis Hernandez
-
Seville, Espanha, 41013
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Irene Carrasco García
-
Valencia, Espanha, 46009
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Hector Augusto Aguilar Andino
-
Zaragoza, Espanha, 50009
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Javier Martínez Trufero
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85258
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Michael Gordon
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
California
-
San Francisco, California, Estados Unidos, 94158
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Victoria Wang
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510-3206
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Philippos Costa
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20817-1802
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ralph Boccia
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64132
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Jaswinder Singh
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130-2042
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Kirsten Leu
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Ciara Kelly
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Juneko Grilley-Olson
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Nashat Gabrail
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Saikrishna Gadde
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Neeta Somaiah
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109-4405
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Min Park
-
-
-
-
-
Helsinki, Finlândia, 00029
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Sari Jaamaa
-
-
-
-
-
Lyon, França, 69373
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Mehdi Brahmi
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Reims, França, 51100
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Olivier Bouché
-
-
-
-
-
Thessaloniki, Grécia, 54639
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Grigorios Rallis
-
Thessaloniki, Grécia, 55535
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ioannis Boukovinas
-
-
Attica
-
Chaïdári, Attica, Grécia, 124 62
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Anastasios Kyriazoglou
-
-
Crete
-
Heraklion, Crete, Grécia, 700 13
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ioannis Souglakos
-
-
-
-
-
Nijmegen, Holanda, 6525GA
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ingrid Desar
-
-
South Holland
-
Leiden, South Holland, Holanda, 2333 ZA
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Hans Gelderblom
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Milan, Itália, 20133
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Elena Rosa Fumagalli
-
Milan, Itália, 20141
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Roberta Giovanna Sanfilippo
-
Palermo, Itália
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Giuseppe Badalamenti
-
Roma, Itália, 00128
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Bruno Vincenzi
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Ehime, Japão, 791-0280
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Tomohiro Nishina
-
Fukuoka, Japão, 812-8582
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Eiji Oki
-
Gifu, Japão, 501-1194
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Nobuhisa Matsuhashi
-
Hokkaido, Japão, 060-8648
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Yoshito Komatsu
-
Kanagawa, Japão, 241-8515
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Hiroki Osumi
-
Osaka, Japão, 565-0871
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Yukinori Kurokawa
-
Tokyo, Japão, 104-0045
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Hidekazu Hirano
-
Tokyo, Japão, 135-8550
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Masato Ozaka
-
Toyama, Japão, 930-0194
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Takayuki Ando
-
Yamaguchi, Japão, 755-8505
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Tatsuya Ioka
-
-
-
-
-
Oslo, Noruega, 0379
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Kjetil Boye
-
-
-
-
-
Warsaw, Polônia, 02-781
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Piotr Rutkowski
-
-
-
-
-
London, Reino Unido, SW3 6JJ
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Robin Jones
-
London, Reino Unido, NW1 2PG
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Vasilios Karavasilis
-
Newcastle upon Tyne, Reino Unido, NE7 7DN
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Anna Stansfeld
-
Sheffield, Reino Unido, S10 2SJ
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Robin Young
-
-
Greater Manchester
-
Manchester, Greater Manchester, Reino Unido, M20 4BX
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Alexander Lee
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Uppsala, Suécia, SE-751 85
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Sharmineh Moghaddam
-
-
-
-
-
Genolier, Suíça, 1272
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Michael Montemurro
-
-
-
-
-
Changhua, Taiwan, 500
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Ruo-Han TSENG
-
Taichung, Taiwan, 404
- Recrutamento
- GSK Investigational Site
-
Investigador principal:
- Li-Yuan Bai
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Taipei, Taiwan, 10002
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Kun-Huei Yeh
-
Taipei, Taiwan, 112
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Chueh-Chuan Yen
-
Taoyuan, Taiwan, 33305
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Chun-Nan Yeh
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).
-
Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.
-
Has not received prior systemic therapy for their metastatic and/or surgically unresectable GIST.
-
Tumor tissue must be provided to the central laboratory. Tumor tissues may be archival (preferred) or obtained from a fresh biopsy acquired for standard of care (biopsies must be collected before randomization).
-
Participants must have ≥1 target lesion (TL).
-
All participants must use adequate contraception according to local regulations throughout the study and for a specified period after the last dose of study medication (at least 30 days for velzatinib/imatinib, or 15 days for imatinib only, as applicable, or longer if local regulations specify).
-
Male participants must either be abstinent or use a male condom (with a recommendation for their female partner to use highly effective contraception). They must also refrain from donating semen.
-
Female participants must not be pregnant or breastfeeding.
- Those of non-childbearing potential are eligible without additional contraception.
- Those of childbearing potential must use an acceptable, highly effective contraceptive method and have a negative pregnancy test before starting the study. The investigator will assess their pregnancy risk.
-
Is capable of giving signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol.
-
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
-
Has adequate organ function.
Exclusion Criteria:
-
Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of metastatic disease.
-
Has any clinically significant gastrointestinal abnormalities that may alter absorption, e.g., malabsorption syndrome or major resection of the stomach and/or bowels.
-
Has had any major surgery (minor surgical procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures) within 14 days of the first dose of study treatment or participants who have not fully recovered from surgery.
-
Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was [>100 days] prior to screening, and b) the participant has no active infection(s) at the time of screening.
-
Has known allergy or hypersensitivity to velzatinib or imatinib, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
-
Has a history within 6 months prior of clinically significant or uncontrolled cardiac disease, unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure [New York Heart Association,1994], or clinically significant arrhythmia not controlled by standard of care therapy, ventricular arrhythmia, cerebrovascular accident or transient ischemic attack and uncontrolled hypertension.
-
Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed [e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases]. Participants with previously treated and clinically stable brain/CNS metastases and who have completed all corticosteroid therapy for ≥2 weeks before randomization are not excluded from participation
-
Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, (excluding e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy) or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.
-
Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).
-
Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.
-
Has received radiotherapy within 14 days prior to first dose of study treatment.
-
Has received any live vaccine within 30 days of randomization. Vaccination against Coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.
-
Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before randomization.
-
Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of medical research before signing ICF.
-
Has a positive drug/alcohol screening assessment.
-
Has a known Human immunodeficiency virus (HIV) infection and meets at least one of the following criteria:
- Has documented evidence of plasma HIV-1 ribonucleic acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
- Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
- Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
- Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
- Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
- Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening.
-
Is pregnant or breastfeeding.
-
Is unable to adhere to the protocol, including requirements for the Follow-up Period of the study.
-
Has an alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or (for participants with documented liver metastases/tumor infiltration) has an ALT value >5x ULN
-
Has a total bilirubin value >1.5x ULN.
-
Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
-
Evidence of chronic hepatitis B virus (HBV) infection with detectable viral load despite antiviral therapy with high resistance barrier.
-
12-lead electrocardiogram (ECG) demonstrating mean QT interval corrected (QTc) corrected by Fridericia's formula >480msec at screening or history of long QT syndrome.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Imatinibe
|
Imatinib will be administered
Outros nomes:
|
|
Experimental: Velzatinib
|
Velzatinib will be administered
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)
Prazo: Up to approximately 74 months
|
PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 74 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with Treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
Prazo: Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Number of participants with TEAEs/SAEs leading to dose reductions, interruptions and treatment discontinuation
Prazo: Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Number of participants with clinically significant changes in vital signs, electrocardiograms, and clinical laboratory parameters
Prazo: Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Plasma concentration of velzatinib
Prazo: Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Confirmed Objective Response Rate (ORR) as assessed by BICR
Prazo: Up to approximately 75 months
|
Confirmed ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response criteria. |
Up to approximately 75 months
|
|
Overall survival (OS)
Prazo: Up to approximately 75 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 75 months
|
|
Confirmed ORR as assessed by Investigator assessment
Prazo: Up to approximately 75 months
|
Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR per response criteria. |
Up to approximately 75 months
|
|
Time from initial study randomization to second disease progression or death (PFS2)
Prazo: Up to approximately 75 months
|
PFS2 is defined as the time from initial study randomization to second disease progression or death after starting the next line of treatment. |
Up to approximately 75 months
|
|
PFS as assessed by Investigator assessment
Prazo: Up to approximately 75 months
|
PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 75 months
|
|
Time to Response (TTR)
Prazo: Up to approximately 75 months
|
TTR as assessed by BICR and investigator, is defined as time from randomization until the first documented PR or CR that was subsequently confirmed. |
Up to approximately 75 months
|
|
Duration of Response (DOR)
Prazo: Up to approximately 75 months
|
DOR as assessed by BICR and investigator, is defined as time from the first documented PR or CR that was subsequently confirmed until the first documented PD or death due to any cause. |
Up to approximately 75 months
|
|
Time to Second Subsequent Therapy (TSST)
Prazo: Up to approximately 75 months
|
TSST is defined as the time from the date of randomization to the earliest date of second subsequent therapy or death due to any cause. |
Up to approximately 75 months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
Prazo: Up to approximately 75 months
|
The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. These include functional scales, symptom scales, global health status scale, and single item scales. Scores are averaged and transformed to 0 to 100. Higher scores indicate greater functioning, better global health status, or more severe symptoms |
Up to approximately 75 months
|
|
Time to confirmed deterioration (TTCD) of EORTC QLQ-C30
Prazo: Up to approximately 75 months
|
TTCD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the Physical & Role Functioning & Global Health Status/QoL scales of the EORTC QLQ-C30. |
Up to approximately 75 months
|
|
Number of participants with symptomatic AEs by severity as measured by patient-reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Prazo: Up to approximately 75 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to approximately 75 months
|
|
Number of participants with bothersome AEs/tolerability as measured by the Functional Assessment of Cancer Therapy - General (FACT-GP5)
Prazo: Up to approximately 75 months
|
The FACT GP5 is an assessment focused on the overall side effects impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5-point Likert type scale. The response scale ranges from 0 (Not at all) to 4 (Very much). Higher scores indicate a higher degree of AE bother. |
Up to approximately 75 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias de Tecidos Conjuntivos e Moles
- Neoplasias do Tecido Conjuntivo
- Tumores Estromais Gastrointestinais
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Ácidos carboxílicos
- Hidrocarbonetos, aromáticos
- Amidas
- Pirimidinas
- Derivados de benzeno
- Ácidos, carbocíclicos
- Benzoates
- Benzamides
- Piperazinas
- Mesilato de Imatinibe
Outros números de identificação do estudo
Outros números de identificação do estudo
- 306293
- 2025-524934-24 (Outro identificador: EU CT Number)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .